Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, Vázquez S, González-Del-Alba A, Piulats JM, Borrega P, Gallardo E, Morales-Barrera R, Paredes P, Reig O, Garcías de España C, Collado R, Bonfill T, Suárez C, Sampayo-Cordero M, Malfettone A, Garde J. Carles J, et al. Eur J Cancer. 2022 Sep;173:317-326. doi: 10.1016/j.ejca.2022.06.057. Epub 2022 Aug 16. Eur J Cancer. 2022. PMID: 35981452 Free article. Clinical Trial.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group. Climent MA, et al. Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29. Crit Rev Oncol Hematol. 2012. PMID: 22285697
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N, Maroto P, Pérez-Valderrama B, Luque R, Méndez-Vidal MJ; cabazitaxel EAP study. Castellano D, et al. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7. Expert Opin Drug Saf. 2014. PMID: 25001524 Clinical Trial.
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J. Climent MÁ, et al. Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Epub 2015 Jun 8. Crit Rev Oncol Hematol. 2015. PMID: 26100652 Review.
New advances in genitourinary cancer: evidence gathered in 2014.
Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A. Suárez C, et al. Cancer Metastasis Rev. 2015 Sep;34(3):443-64. doi: 10.1007/s10555-015-9577-x. Cancer Metastasis Rev. 2015. PMID: 26227584 Review.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Lainez N, et al. BMC Cancer. 2016 Feb 22;16:135. doi: 10.1186/s12885-016-2084-9. BMC Cancer. 2016. PMID: 26906039 Free PMC article.
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J. Cebrián A, et al. Sci Rep. 2017 Jan 24;7:41371. doi: 10.1038/srep41371. Sci Rep. 2017. PMID: 28117391 Free PMC article.
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Puente J, et al. Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494. Oncotarget. 2017. PMID: 28423742 Free PMC article.
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. González Del Alba A, et al. Crit Rev Oncol Hematol. 2017 May;113:171-190. doi: 10.1016/j.critrevonc.2017.03.010. Epub 2017 Mar 14. Crit Rev Oncol Hematol. 2017. PMID: 28427506 Review.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Conteduca V, et al. Ann Oncol. 2017 Jul 1;28(7):1508-1516. doi: 10.1093/annonc/mdx155. Ann Oncol. 2017. PMID: 28472366 Free PMC article. Clinical Trial.
62 results